HD-OPM Archive
Topics › PCSK9, ezetimibe & newer drugs

No trial shows PCSK9 inhibitor monotherapy cuts heart attacks; HORIZON undermines Lp(a)

Louis Nervegna · Oct 31, 2026 · ♥ 16 reactions · 32 comments · original Facebook post
PCSK9, ezetimibe & newer drugsLp(a)Statins
AI summary & key facts

Louis argues guidelines recommend against PCSK9 inhibitor monotherapy as first-line primary prevention because no randomized trial shows it lowers heart attacks, strokes or CVD mortality. He adds that the HORIZON trial massively lowered Lp(a) but had no effect on MACE, so people on PCSK9i mainly to lower Lp(a) should revisit that choice, since statins or statins plus PCSK9i are proven even with high Lp(a).

There are no randomized trials that have ever shown that PCSK9 inhibitors as a monotherapy lower the risk of heart attacks, strokes, or cardiovascular mortality.

There is a very good reason why all the evidence-based guidelines recommend against using PCSK9 inhibitors as a first-line monotherapy therapy for primary prevention. There are no evidence-based outcome trials to support doing this.

As a monotherapy, they are reserved as backup for when proven first line therapies fail or are not tolerated. Or they are combined with statins for higher risk patients, because that is the case where randomized outcome trials have actually shown proven reductions in heart attacks, strokes, and CVD mortality.

Also see this past post on the subject: ↪ No trial has shown PCSK9 inhibitors lower heart attack risk without statins.

I want to add one more comment regarding Lp(a):

The recent release of data from the HORIZON trial has seriously called into question the idea that interventions which lower Lp(a) actually reduce heart attacks and strokes. The HORIZON trial massively lowered Lp(a), but had no effect on MACE: ↪ After the Novartis pelacarsen Lp(a) trial failed, doubts arise about Lp(a) as a cause.

If you are taking PCSK9 monotherapy mainly to lower Lp(a), it is probably time to revisit that decision. Many outcome trials have proven that statins alone or statins+PCSK9i lower risk of heart attacks and strokes in people with high Lp(a). The same cannot be said for PCSK9i monotherapy.

#pcsk9HD #pcsk9monotherapyHD #guidelinesHD #statinsHD #statinspcsk9HD

Research cited

← newer: Lewy body dementia is common and often missed; ApoE4 overlapolder: Green Mediterranean diet cut visceral fat about 14% in an 18 →